Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism

Value Health. 2014 Nov;17(7):A475. doi: 10.1016/j.jval.2014.08.1358. Epub 2014 Oct 26.

Authors

M Hamilton¹, H Phatak¹, T Lanitis², J Mardekian³, D A Rublee³, R Leipold⁴, P Quon⁴, C Browne², A T Cohen⁵

Affiliations

¹ Bristol-Myers Squibb Company, Princeton, NJ, USA.
² Evidera, London, UK.
³ Pfizer, Inc., New York, NY, USA.
⁴ Evidera, Bethesda, MD, USA.
⁵ Guy's and St Thomas' NHS Foundation Trust, London, UK.

PMID: 27201370
DOI: 10.1016/j.jval.2014.08.1358

No abstract available